Assembly Bio Q2 Loss Narrows to $3.9M; Cash Runway Extended into 2029
ASMB sits 48% above its 52-week low of $20.23 on elevated volume (3.4× avg).
Summary
Assembly Bio reported a narrower Q2 loss, extended cash runway into 2029, and advanced two key pipeline programs toward Phase 2 trials.
Key Events · Earnings and Guidance · ASMB
-
Q2 Net Loss Narrows to $3.9M
Net loss of $3.9 million ($0.20/share) compared to $10.2 million ($1.33/share) in Q2 2025, driven by higher collaboration revenue and lower R&D expenses.
-
Cash Runway Extended into 2029
Cash, cash equivalents and marketable securities totaled $320.4 million as of June 30, 2026, with projected runway into 2029 including a $75 million Gilead extension payment due in Q4 2026.
-
GS-1179 Advances to Phase 2
Gilead selected GS-1179 (formerly ABI-1179) to advance in the HSV helicase-primase inhibitor program, with Phase 2 initiation expected by year-end 2026.
-
ABI-6250 Expands into Cholestatic Liver Diseases
Phase 2 study for ABI-6250 in cholestatic liver diseases (PBC and PSC) anticipated to initiate in Q1 2027, alongside a Phase 2 study in chronic HDV by year-end 2026.
Analysis · ASMB · Life Sciences
A significantly narrower Q2 net loss of $3.9 million versus $10.2 million a year ago was driven by higher Gilead collaboration revenue and lower R&D spending. The company's cash position of $320.4 million, bolstered by the recent $115 million financing, is projected to fund operations into 2029. Pipeline momentum is strong: GS-1179 has been selected to advance in the HSV program with Phase 2 initiation expected by year-end 2026, and ABI-6250 is expanding into cholestatic liver diseases with a Phase 2 study planned for Q1 2027. A $75 million Gilead extension payment is also expected in Q4 2026, further strengthening the balance sheet.
How filings like this one have moved
In the 30 days to Aug 22, 2026, 29.1% of the 2927 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASMB was trading at $29.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $593.5M. The 52-week trading range was $20.23 to $39.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.